Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
95 hedge funds and large institutions have $132M invested in Y-mAbs Therapeutics in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 10 closing their positions.
227% more call options, than puts
Call options by funds: $36K | Put options by funds: $11K
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
39% more capital invested
Capital invested by funds: $95.4M → $132M (+$37M)
12% more funds holding
Funds holding: 85 → 95 (+10)
1.17% more ownership
Funds ownership: 43.48% → 44.65% (+1.2%)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$3.63M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$2.03M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.91M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.8M |
| 5 |
Goldman Sachs
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.2M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.15M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.05M |
| 5 |
JP Morgan Chase
New York
|
-$1.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DTL
101
Dynamic Technology Lab
Singapore
| – | -$128K | -25,478 | Closed |
|
|
VF
102
Virtu Financial
New York
| – | -$126K | -25,147 | Closed |
|
103
SG Americas Securities
New York
| – | -$109K | -21,735 | Closed |
|
|
PVH
104
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$3K | -800 | Closed |
|
105
Simplex Trading
Chicago,
Illinois
| – | +$360 | +48 | New |
|
YMAB Hedge Fund Activity: Q2 2023 in Review
95 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2023, worth a combined $132M — up 39% from $95.4M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new YMAB positions and 10 closed out — a net gain of 10 holders — while 32 added to existing stakes and 30 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $3.63M. The largest seller was Millennium Management, cutting an estimated $2.2M.
- 95 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2023, up from 85 in Q1 2023.
- Funds reported $132M of Y-mAbs Therapeutics stock for Q2 2023, up 39% quarter-over-quarter.
- 20 funds opened new Y-mAbs Therapeutics positions in Q2 2023 and 10 closed out, a net change of +10 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2023 was D.E. Shaw & Co, an estimated $3.63M added.
- The largest Y-mAbs Therapeutics seller in Q2 2023 was Millennium Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q2 2023.